Elixir Pharmaceuticals, Inc., today announced the Company has entered an exclusive license agreement with Boston University to key intellectual property covering discoveries regarding the use of modulators of SIRT1, a member of the sirtuin class of protein deacetylase enzymes.

Elixir Pharmaceuticals, Inc., today announced that results from in-vivo preclinical studies with the Company's ghrelin agonist, EX-1314, were presented at the annual meeting of the Endocrine Society. EX-1314 is expected to enter human clinical testing this year.

Elixir Pharmaceuticals, Inc., today announced new data validating ghrelin, a potent, naturally occurring hormone, as a master regulator of metabolism.

Elixir Pharmaceuticals, Inc., today announced publication in a peer-reviewed journal of new data that further establish ghrelin, a potent, naturally occurring hormone, as a master regulator of metabolism.

Elixir Pharmaceuticals, Inc., announced today the formation of its U.S.